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COMMENT 
COMPOUNDING REFORM: RECONSIDERING THE DRAFT 
SAFE DRUG COMPOUNDING ACT OF 2007 IN LIGHT OF THE 
ONGOING FUNGAL MENINGITIS OUTBREAK 
Colleen Nicholson* 
Compounding is the act of combining, mixing or altering 
ingredients to create a drug tailored to the needs of an individual 
patient, such as a child who needs a less potent dose, an elderly 
patient who has trouble swallowing, or an individual with a severe 
allergy to a drug component. Compounding pharmacies, which 
engage in large-scale drug compounding, have come under the 
microscope recently because of the ongoing deadly outbreak of 
fungal meningitis that began in 2012. Fungal meningitis “occurs 
when the protective membranes covering the brain and spinal 
cord are infected with a fungus.”1 The recent outbreak was caused 
by steroid shots contaminated with so much fungus that in some 
cases the fungus particles were visible to the naked eye.2 A single 
compounding pharmacy in Framingham, Massachusetts, the New 
England Compounding Center, “shipped 17,676 vials of . . . 
potentially contaminated [steroid] solution to 75 clinics in 23 
states.”3 As of March 4, 2013, the Centers for Disease Control and 
Prevention (CDC) had linked 720 cases of meningitis or other 
complications, including forty-eight deaths, in twenty states to the 
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epidural steroid injections that all originated from the New 
England Compounding Center.4 
However, the New England Compounding Center is a 
relatively small compounding pharmacy, with $32.4 million in 
annual sales for 20125 in comparison to estimates that there are 
“between 800 and 900 compounding pharmacies with sales in 
excess of $2 billion a year.”6 Additionally, the contaminated 
steroid solution linked to the current fungal meningitis outbreak 
is not an isolated incident, as historically more than “one million 
doses of compounded drugs have been recalled for bacterial or 
fungal contamination.”7 
Currently, compounding is a matter for individual state 
pharmacy boards to regulate.8 State compounding pharmacy 
oversight regimes vary widely in terms of requirements and 
resources, and the proliferation of Mail-Order and Internet 
pharmacies whose patients are often across state lines has 
stretched the regulatory abilities of the state pharmacy boards.9 
Therefore, Congress should resuscitate the Safe Drug 
Compounding Act of 2007 to give the Food and Drug 
Administration (FDA) the power to regulate large-scale 
compounding pharmacy operations to prevent future outbreaks 
like the recent fungal meningitis outbreak from occurring. 
In 2007, Senators Edward Kennedy, Richard Burr and Pat 
Roberts proposed the Safe Drug Compounding Act of 2007, which 
would have increased the FDA’s role in regulating compounded 
drugs.10 The twenty-four page draft bill11 proposed amending the 
4. Multi-State Meningitis Outbreak – Current Case Count, CTRS. FOR DISEASE
CONTROL AND PREVENTION, http://www.cdc.gov/hai/outbreaks/meningitis-map.html (last 
visited Mar. 7, 2013). 
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Federal Food, Drug, and Cosmetic Act to allow the FDA to 
regulate compounding pharmacies, restrict interstate distribution 
of compounded products, and establish federal requirements for 
sterile compounding.12 Enacting the proposed Safe Drug 
Compounding Act of 2007 would thus enable the FDA to fill in 
the gaps left by state pharmacy boards. The bill was opposed by 
pharmacy trade groups including the International Academy of 
Compounding Pharmacists because of the perception that such 
regulation would limit patient access to medically necessary 
compounded prescriptions.13 The bill never came to a vote in the 
Senate.14 
However, FDA regulation would primarily target larger-scale 
interstate operations like the New England Compounding Center 
rather than, for example, the pharmacist who compounds the 
occasional prescription for an infant who needs a smaller dose 
than is commercially produced. The Safe Drug Compounding Act 
of 2007 explicitly preserved the ability of pharmacists and 
physicians to compound drug products for an identified individual 
patient.15 Therefore, the draft text does not deny patients 
medically necessary compounded drugs. 
Under the Safe Drug Compounding Act of 2007, state 
pharmacy boards can continue regulating compounded drugs 
prepared for individual patients. Bringing large-scale 
compounding pharmacies under federal oversight will heighten 
manufacturing standards and subject drugs compounded in large 
batches to FDA inspection. Further, restricting the interstate 
distribution of such drugs will ensure that future outbreaks 
because of contamination will be limited in scope. In other words, 
having a federal regulatory regime in place for large-scale 
compounded drugs could have prevented or severely limited the 
11. Safe Drug Compounding Act of 2007, 110th Cong. (2007) (discussion draft),
available at http://www.theempowermentcentre.com/uploads/DiscussionDraftCompounding 
Bill.pdf. 
12. See Carol Lam, Pharmacy Compounding – Regulatory Issues, S. CAL. REG. SCI. J. 
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ongoing outbreak of fungal meningitis. Therefore, in light of the 
tragic outbreak of fungal meningitis, Congress should enact the 
Safe Drug Compounding Act of 2007 to improve the safety of 
large-scale compounded drugs. 
